Benitec Biopharma Ltd
ABN 64 068 943 662
F6A / 1-15 Barr Street
Balmain NSW 2041 Australia
Tel: +61 (0) 2 9555 6986
Email: info@benitec.com
www.benitec.com

ASX ANNOUNCEMENT

BENITEC ROADSHOW INVESTOR PRESENTATION

Sydney, 11 June 2014: Benitec Biopharma Limited (ASX: BLT) (OTC: BTEBY) is pleased to release a copy of the presentation that Dr Peter French, CEO and Managing Director, will be delivering to investors during a non-deal roadshow in the USA during June.

The presentation highlights Benitec's progress on the company's ddRNAi programs and provides an update on the establishment of the California laboratory

For further information, please contact the persons below, or visit the Benitec website at www.benitec.com.

Company	***Investor relations***
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) (OTC Code: BTEBY) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.

BENITEC BIOPHARMA
silencing genes for life™

Gene Silencing using ddRNAi: Update on progress

June 2014

Forward looking statement

This presentation contains forward looking statements that involve risks and uncertainties.

Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Benitec Biopharma can give no assurance that these expectations will prove to be correct.

Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors.

This document does not constitute an offer, solicitation or recommendation in relation to the subscription, purchase or sale of securities in any jurisdiction. Neither this presentation nor anything in it will form any part of any contract for the acquisition of securities.

Company Financial Snapshot

Key Financials	ASX:BLT OTC: BTEBY
Share Price as at close of trade 3 June 2014:	AUD $1.10
Market Capitalisation (fully diluted) as at 3 June 2014:	AUD $126.4M
Issued Securities as at 29 April 2014: Ordinary shares Options	 114,895,525 23,140,177
Cash balance at 31 March 2014:	AUD $18.4 M

Access to Benitec Biopharma via U.S. OTC Market

ADR Benefits to U.S. Investors:

- ADRs give direct access to our listed equity capital base allowing participation in cross-border market liquidity
- Company disclosure via OTC website
- ADRs are cost-effective
- ADRs are convenient to transact and own
- Quoted in U.S. dollars
- Settle via standard U.S securities settlement process
- Program is administered by a market leading global depositary

Benitec Biopharma ADR trading info:

Symbol	BTEBY
CUSIP	082053208
Ratio	1 ADR : 5 ORDs
Country	Australia
Effective Date	May 30, 2014
Underlying SEDOL	6710507
Underlying ISIN	AU000000BLT8
Depositary	BNY Mellon

For more information, please call The Bank of New York Mellon marketing desks:

- **London**
  BNYM
  Mark Lewis
  mark.lewis@bnymellon.com
  Telephone +44 207 163 7407
- **New York**
  BNYM
  Kristen Resch
  kristen.resch@bnymellon.com
  Telephone +1 212 815 2213
- **New York**
  BNYM
  Angelo Fazio
  angelo.fazio@bnymellon.com
  Telephone +212 815 2893
- **Hong Kong**
  BNYM
  Herston Powers
  herston.powers@bnymellon.com
  Telephone +852 2840 9868

ddRNAi Technology
The next revolution in gene silencing

- **A specific and long lasting method for turning off disease-associated genes**
- **ddRNAi technology utilises the power and specificity of RNAi while avoiding many of its problems**
  - Specific delivery to target cells
  - Fewer side effects
  - Lasting benefits –dsRNA generated continuously for the life of the cell
  - Multiple therapy in a single molecule - can be engineered to silence a specific gene, multiple sites on a gene or multiple genes
- **Protected by a dominant, global patent estate - over 100 patents covering ddRNAi and specific disease targets**



In-house programs

Focus	Indication	Partners / Collaborators	Discovery	Pre-clinical	Clinical
Infectious Disease	Hepatitis C				
	Hepatitis B	Biomics Biotechnology (JV)			
Cancer	Non Small Cell* Lung Cancer	University of New South Wales (RC)			
	Cancer Associated Pain	Stanford University (RC)			
Ocular Disease	AMD**				
Genetic Disease	OPMD***	Royal Holloway London University (RC)			

RC = research collaboration
JV = joint venture

*and other chemotherapy-resistant cancers **Age-Related Macular Degeneration
***Oculopharyngeal Muscular Dystrophy, an orphan disease

Sub-licensed programs

Focus	Indication	Partners/Collaborators	Discovery	Pre-clinical	Clinical
Infectious Disease	HIV/AIDS	**Licensed to Calimmune**			
Cancer	Cancer Vaccines	**Licensed to Regen BioPharma**			
Ocular Disease	Retinitis Pigmentosa	**Licensed to Genable**			
Genetic Disease	Huntington's Disease	**Licensed to uniQure**			

TT-034 Update

- **TT-034 is an RNAi therapeutic that is intended as a "one-shot-cure"**
- **Goal is to achieve complete and sustained elimination of virus with a single infusion**
- **US-based open-label dose-escalation Phase I/IIa trial underway**
  - Regulatory activity:
    - ✓ **Patient dosing commenced** May 29, 2014
    - ✓ FDA released IND January 12, 2014 within 30 days of submission with no major questions
    - ✓ Protocol reviewed and approved by NIH RAC June 2013 with unanimous panel support

- **Trial sites**
  - Duke Clinical Research Unit, North Carolina - currently dosing & continuing to screen additional patients
  - University of California, San Diego – finalising agreement

Phase I/IIa Dose Cohorts

Cohort	Dose (vg/kg)	Dose escalation step (log 10)	Total No subjects	Dosing scheme for subjects	Observation period per subject and between cohorts before dose escalation
1	4.00×10^{10}	Starting dose	2	Sequential (1+1)	6 week
2	1.25×10^{11}	0.5	3	Sequential and parallel (1+2)	6 week
3	4.00×10^{11}	0.5	3	Sequential and parallel (1+2)	6 week
4	1.25×10^{12}	0.5	3	Sequential and parallel (1+2)	10 weeks
5	4.00×10^{12}	0.5	3	Sequential and parallel (1+2)	10 weeks

- DSMB review after first patient in each cohort and between cohorts
- Extensive safety monitoring during 24 weeks observation

TT-034:
Clinical Trial Implications

- Expect interim safety data 2H 2014
- Expect efficacy data 1H 2015 – positive results should be a significant value inflection milestone for Benitec
- Clinical demonstration of a "game changer" for treatment of HCV - As a "single shot cure," TT-034 would compete with small molecule cocktails:
  - Compliance, side effect profile, efficacy, cost effectiveness
- Provides a validation of Benitec's other pipeline programs – for safety, efficacy
- Will provide clinical data and leverage for partnering discussions

Drug resistant lung cancer: Tribetarna™ Update

- **Tribetarna Proof of Principle established:**
  - A single injection of Tribetarna™ effectively silences the βIII tubulin gene
  - Tribetarna™ significantly enhances survival in a preclinical model of lung cancer in combination with chemotherapy
- **A Phase I/IIa clinical trial of Tribetarna™ in conjunction with cisplatin is being prepared**
  - Undertaken prep-preIND meeting with US FDA
  - Manufacture of GLP Product for reg/tox studies underway
  - European CRO appointed – CTG CRO

With clinical success in lung cancer, this approach can be developed to target other cancers that express high βIII tubulin (breast, ovarian & gastric)

AMD Update

Age-related macular degeneration (AMD) – A single injection of a ddRNAi construct to replace current standard of care (monthly injections into the eyeball).



- Constructs designed and tested:





- Advanced negotiations for a suitable vector for delivery of ddRNAi therapy
- Research collaborator identified – primate model validation

Hepatitis B Update

A replica of TT-034 approach. 350 million people infected worldwide, major unmet medical need – substantial interest from Big Pharma

- Strategy to leverage success of RNAi therapies utilising long term benefit of ddRNAi
- Expanded collaboration with Biomics
  - Sequence validation – homology search completed
  - Optimisation of construct in progress
  - Animal model of HBV identified



[1]Negotiations completed in principle not yet announced

Additional Activities

- **Appointed R&D Program Manager to accelerate progress on pre-clinical programs**
- **Established laboratory facility in California**
  - Recruited 2 scientists – ex Tacere supporting Dr Suhy
  - Principle activities
    - Advance pre-clinical testing for AMD, HBV and pain programs
    - Validate alternative DNA manufacturing technology [1]
    - Test and review new delivery options[1]
- **Negotiated enhanced agreement with Professor Yeomans at Stanford University to identify and validate additional targets for Cancer Associated Pain Program**
- **Identifying and reviewing feasibility of additional ddRNAi disease targets**

[1]Providing additional IP protection & expansion